VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. Blackwell on Emerging Therapies in TNBC

Kimberly L. Blackwell, MD
Published: Friday, Nov 06, 2015



Kimberly L. Blackwell, MD, medical oncologist, Duke Cancer Institute, discusses emerging therapies for patients with triple-negative breast cancer (TNBC).

Blackwell discusses recent data examining standard chemotherapy for the treatment of TNBC. One example is the TNT study, which demonstrated that in BRCA-mutated patients, carboplatin leads to a doubled objective response compared with single-agent docetaxel. A second study, which examined the efficacy of eribulin versus capecitabine in TNBC, showed that eribulin had an overall survival advantage compared with capecitabine.

Overall, Blackwell says that researchers are making progress with standard chemotherapy for the treatment of TNBC.

<<< View more from the 2015 CFS Annual Meeting



Kimberly L. Blackwell, MD, medical oncologist, Duke Cancer Institute, discusses emerging therapies for patients with triple-negative breast cancer (TNBC).

Blackwell discusses recent data examining standard chemotherapy for the treatment of TNBC. One example is the TNT study, which demonstrated that in BRCA-mutated patients, carboplatin leads to a doubled objective response compared with single-agent docetaxel. A second study, which examined the efficacy of eribulin versus capecitabine in TNBC, showed that eribulin had an overall survival advantage compared with capecitabine.

Overall, Blackwell says that researchers are making progress with standard chemotherapy for the treatment of TNBC.

<<< View more from the 2015 CFS Annual Meeting


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x